Journal article

Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype

Mia M Gaudet, Gretchen L Gierach, Brian D Carter, Juhua Luo, Roger L Milne, Elisabete Weiderpass, Graham G Giles, Rulla M Tamimi, A Heather Eliassen, Bernard Rosner, Alicja Wolk, Hans-Olov Adami, Karen L Margolis, Susan M Gapstur, Montserrat Garcia-Closas, Louise A Brinton

CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2018

Abstract

Various subtypes of breast cancer defined by estrogen receptor (ER), progesterone receptor (PR), and HER2 exhibit etiologic differences in reproductive factors, but associations with other risk factors are inconsistent. To clarify etiologic heterogeneity, we pooled data from nine cohort studies. Multivariable, joint Cox proportional hazards regression models were used to estimate HRs and 95% confidence intervals (CI) for molecular subtypes. Of 606,025 women, 11,741 invasive breast cancers with complete tissue markers developed during follow-up: 8,700 luminal A-like (ER+ or PR+/HER2-), 1,368 luminal B-like (ER+ or PR+/HER2+), 521 HER2-enriched (ER-/PR-/HER2+), and 1,152 triple-negative (ER-/P..

View full abstract

Grants

Awarded by Australian NHMRC


Awarded by NCI


Awarded by Swedish Research Council


Awarded by Distinguished Professor Award at Karolinska Institutet


Awarded by U.S. Department of Health and Human Services


Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

The pooling project was sponsored by the NCI's Cohort Consortium and funded by the intramural research program at the American Cancer Society. The American Cancer Society funds the creation, maintenance, and updating of the CPS-II cohort. The MCCS receives core funding from the Cancer Council Victoria and is additionally supported by grants from the Australian NHMRC (209057, 251533, 396414, and 504715). The NIH-AARP Diet and Health Study (AARP) was supported by the Intramural Research Program of the NCI, NIH. The NHS1 was supported by grants from the NCI (UM1CA186107 and P01CA087969). The NHS2 was supported by a grant from the NCI (UM1CA176726 and R01 CA050385). The PLCO Cancer Screening Trial is supported by contracts from the NCI. The SMC was supported by the Swedish Research Council, Swedish Council for Working Life and Social Research, and the Swedish Cancer Foundation. The SWLH was supported by the Swedish Research Council (grant number 521-2011-2955) and a Distinguished Professor Award at Karolinska Institutet to Hans-Olov Adami, grant number: 2368/10-221. The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, and U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.